Clinical Study of 3DCRT Combined with SBRT in the Treatment of Patients with EGFR Mutation Oligometastatic Non-Small Cell Lung Cancer

BACKGROUND: Lung cancer is one of the malignant tumors with the highest morbidity and mortality in my country and the world. Among them, non-small-cell lung cancer (NSCLC) accounts for about 80%. For patients who are diagnosed with NSCLC and have epidermal growth factor receptor, EGFR gene-sensitive mutations The treatment is particularly important. AIMS: To investigate the efficacy and prognosis of 3DCRT combined with local SBRT in patients with EGFR mutation oligometastatic NSCLC. MATERIALS AND METHODS: Eighty patients with EGFR mutation oligometastatic NSCLC were selected by random remainder grouping method. 3DCRT combined with SBRT is effective and safer in patients with EGFR-mutant oligometastatic NSCLC, and significantly improves the patient's immune and tumor marker levels. It has a certain reference value in the clinical treatment of EGFR-mutant oligometastatic NSCLC.